PT - JOURNAL ARTICLE AU - Shinkai, Masaharu AU - Sonoyama, Takuhiro AU - Kamitani, Akari AU - Shibata, Risa AU - Seki, Naomi AU - Omoto, Shinya AU - Shinoda, Masahiro AU - Sato, Takashi AU - Ishii, Naoki AU - Igarashi, Kenji AU - Ariyasu, Mari TI - Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study AID - 10.1101/2022.03.03.22271827 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.03.22271827 4099 - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271827.short 4100 - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271827.full AB - In this randomized, observer-blinded, phase 2/3 study, we assessed S-268019-b—a recombinant spike protein vaccine. We analyzed the noninferiority of S-268019-b (n=103), versus tozinameran (n=103), when given as a booster ≥6 months after the 2-dose tozinameran regimen in Japanese adults without prior COVID-19 infection. Interim results showed that S-268019-b was noninferior to tozinameran in co-primary endpoints: geometric mean titer (GMT) (126.42 versus 108.20; adjusted-GMT ratio [95% CI], 1.17 [0.96-1.42]; noninferiority P-value, <0.0001) and seroresponse rate (both 100%; noninferiority P-value, 0.0004) for neutralizing antibodies on day 29. Both vaccines elicited anti-spike protein immunoglobulin G antibodies, and produced T-cell response (n=30/group) and neutralized Delta and Omicron pseudovirus variants (n=24/group) in subgroups. Most participants reported low-grade reactogenicity on days 1 and 2, the most frequent being fatigue, fever, myalgia, and injection-site pain. No serious adverse events were reported. S-268019-b safety and robust immunogenicity as a booster, supporting its use as COVID-19 booster vaccine.JRCT ID jRCT2031210470HighlightsThird COVID-19 vaccine dose (booster) enhances immune responseInterim phase 2/3 data for booster ≥6 months after the 2nd dose in Japan are shownS-268019-b and tozinameran were safe and equal in inducing neutralizing antibodiesBoth boosters neutralized Delta and Omicron pseudovirus and induced T-cell responseResults support use of S-268019-b as a booster in vaccinated adultsCompeting Interest StatementThis work was supported by Shionogi & Co., Ltd., and Ministry of Health, Labour and Welfare (MHLW) under its supplementary budget for emergency maintenance associated with the vaccine production system. Preparation of clinical trial materials of S-268019-b was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP21nf010626. M. Shinkai, M. Shinoda, T. Sato, and N. Ishii have no conflicts of interest to declare. TS, AK, RS, NS, SO, KI, and MA are employees of Shionogi & Co., Ltd.Clinical TrialjRCT2031210470Funding StatementThis work was supported by Shionogi & Co., Ltd., and Ministry of Health, Labour and Welfare (MHLW) under its supplementary budget for emergency maintenance associated with the vaccine production system. Preparation of clinical trial materials of S-268019-b was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP21nf010626.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study (jRCT2031210470) was conducted in compliance with the protocol, the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines, other applicable laws and regulations, and was approved by Institutional Review Board of Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai. All participants gave their written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.